Schedule a Meeting
Download Brochure
Table of Content
April 2025
Principal Consultant
Reviewed By
The global protein therapeutics market size is calculated at US$ 375.3 in 2024, grew to US$ 401.89 billion in 2025, and is projected to reach around US$ 740.07 billion by 2034. The market is expanding at a CAGR of 7.08% between 2025 and 2034.
| Metric | Details |
| Market Size in 2024 | USD 375.3 Billion |
| Projected Market Size in 2034 | USD 740.07 Billion |
| CAGR (2025 - 2034) | 7.08% |
| Leading Region | North America |
| Market Segmentation | By Product, By Applications, By Region |
| Top Key Players |
Daiichi Sankyo Company, Bayer AG, Abbott, Bristol-Myers Squibb, Genzyme Corporation (Sanofi), Sanofi, AbbVie, Inc., Thermo Fisher Scientific, Inc., Amicus Therapeutics, Leadiant Biosciences |
The natural proteins recombinant types were the primary protein therapeutics. To maximize the clinical potential, followed by improvements by proteins or glycoengineering, Fc conjugation or fusion with polyethylene glycol was carried out to modify the proteins. Furthermore, antibody-based protein therapeutics are rising due to their effectiveness. The merging of scientific, technological, commercial, and clinical drivers can offer different approaches and address the rationale for the development of protein therapeutics with better safety, improved delivery, decreased immunogenicity, as well as improved efficacy. Moreover, new platform technologies as well as new engineered protein scaffolds are being developed to offer more advantages over antibody-based protein therapeutics.
By integrating AI as well as machine learning with protein science can gain a whole understanding of cell and proteome homeostasis. Thus, by utilizing human knowledge in AI and machine learning, various protein structures can also be predicted. At the same time, processes such as protein adjustments, fitness, and self-organization can also be identified. Hence, various new protein therapeutics, protein networks, novel proteins, as well as artificial metabolic pathways, can be discovered and developed easily. Similarly, various models that predict the stability and interaction of proteins have also been developed. Furthermore, by identifying the lifestyle, genomic information, and medical history, personalized medication can be formulated. Thus, AI algorithms can further help in minimizing the cost and time associated with the development process.
Increasing Diseases
Due to rising population and lifestyle changes, the occurrences of various diseases are rising. Thus, different types of chronic disorders such as cancer, autoimmune disorders, hematological disorders, diabetes, rare diseases, etc., are rising in geriatric as well as in infants. This has increased the need for protein therapeutics as well as protein-based biologics and biosimilars. At the same time, the development of new protein treatment approaches that provide targeted and personalized medications is also rising. Furthermore, vaccines are also being developed for a variety of infections. Thus, this in turn promotes the protein therapeutics market growth.
The graph represents a comparison between the estimated rates of blood cancer and blood disorders in Australia in the year of 2022 and 2035. It indicates that there will be a rise in hematological disorders, which will lead to an increased demand for protein therapeutics as treatment options. Thus, this in turn will ultimately promote the market growth.
Limited Stability
Protein denatures due to their sensitivity to heat, light, enzymatic degradation, as well as pH. This can lead to the aggregation or decrease in their effectiveness, or sometimes even become unsafe to use. Furthermore, due to short shelf life, they require cold temperatures, which can lead to problems during transportation or distribution. Thus, all these factors can decrease the stability of protein therapeutics, causing limited access.
Rising Rare Disease Therapeutics
Patients suffering from rare diseases show the absence or malfunctioning of proteins, enzymes, or genes. Thus, this increases the need for protein therapeutics. Personalized treatment options can be made available to patients by using protein therapeutics for formulating them. Furthermore, target-specific mechanisms can also be used to enhance the action and reduce the side effects of the treatments. Similarly, protein or enzyme replacement can be carried out using protein therapeutics. Thus, all these factors enhance the protein therapeutics market growth.
For instance,
By product type, the monoclonal antibodies segment dominated the market in 2024. The monoclonal antibodies showed a wide range of applications in different diseases with increased specificity. This, in turn, improved the patient outcomes, and the approval rate increased, which contributed to the protein therapeutics market growth.
By product type, the insulin segment is estimated to grow significantly at a notable CAGR during the forecast period. The use is rising due to the increasing diabetes patients. It provided longer blood sugar control, reducing the dose administration, resulting in an increased acceptance rate.
By application type, the metabolic disorders segment dominated the protein therapeutics market in 2024. The increased incidence of metabolic disorders caused an increased use of protein therapeutics. Due to their advantages, such as improved target specificity, safety, and efficacy increased their demand as well as increased the market growth.
By application type, the immunological disorders segment is anticipated to grow significantly during the forecast period. The protein therapeutics provide effective results in managing the rising immunological disorders. This, in turn, is growing their demand in the market.
North America dominated the protein therapeutics market in 2024. North America consisted of well-established industries that focused on the development of new protein therapeutics. This was further supported by the government investments as well as technological advancements. Thus, all these factors contributed to the market growth.
Various industries in the U.S., as well as institutions, are developing new treatment strategies because of rising diseases. At the same time, there is a rise in the demand for protein therapeutics due to their enhanced effectiveness, which is also enhancing the manufacturing process.
The rising demand for protein therapeutics has increased the manufacturing as well as the new development process. This, in turn, has increased the interest within the institutions, leading to new collaborations, which are supported by the government and private sectors.
Asia Pacific is estimated to host the fastest-growing protein therapeutics market during the forecast period. In Asia Pacific, due to the rising population, the people infected with diseases is also rising. This is increasing the demand for new protein-based treatment options, which in turn, is promoting the market growth.
Due to the large population in China, the occurrences of diseases are rising. This has increased the demand for new protein therapeutics for the effective management of these diseases. Furthermore, the advanced technologies and the government support are raising the production rates.
The incidence of various diseases in the growing population has increased the need for protein-based treatments. Thus, the industries as well as hospitals are developing and adapting to such new strategies. Furthermore, the government is also supporting them to make these treatments affordable.
Europe is expected to grow significantly in the protein therapeutics market during the forecast period. Europe is experiencing an increased interest in research conducted by both industries and institutions in protein therapeutics. This, in turn, is increasing the protein-based treatment options for various diseases. Thus, the government and regulatory agencies are also supporting it, which promotes the market growth.
Germany consists of a large number of industries as well as institutions that are focusing on the research of new protein-based treatment approaches. Different types of research are being conducted to develop treatments that can be used for various disorders. Furthermore, this is also increasing the collaborations between the industries as well as institutions.
For the development of personalized medications, various research is being conducted in the industries and institutions in the UK. These are further supported by the funding provided by the government as well as by regulatory agencies during the approval process.
By Product
By Applications
By Region
April 2025
April 2025
April 2025
March 2025